FDA Warning Letters 94% In Concurrence With Chief Counsel At Six Months
This article was originally published in The Gray Sheet
Executive Summary
FDA warning and "untitled" letters are in sync with the Office of the Chief Counsel's interpretations a significant majority of the time, based on a six-month review of the policy that shifted warning letter authority from the field to the legal office